Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study found that Han Chinese women carrying the rs6152A allele had a significantly higher risk of developing polycystic ovary syndrome compared to those with the rs6152GG genotype.

This study detailed the implementation of an autonomous AI device in an NHS skin cancer pathway, showing that it achieved a sensitivity of 97.3% for diagnosing skin cancers and exceeded sensitivity targets compared to specialists with a negative predictive value over 99.7%.

This study found that keratin intermediate filaments in the hair of GAN patients are altered, showing decreased diffraction signals and increased stiffness, strength, and extensibility.

This study suggests that while adding baricitinib to formularies may increase costs for government hospitals, it could expand treatment options and potentially improve outcomes for patients with AA. Further analyses are recommended to assess its cost-effectiveness in terms of outcomes improvement.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study reports on a new semantic annotation approach used to identify substances in MEDLINE abstracts responsible for adverse drug reactions, with promising performance shown by a prototype system.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

This study used the "ARE-Luc" mouse model to visualize androgen receptor activity across various tissues in both male and female mice, highlighting the direct action of androgens outside reproductive organs.

This study examines the use and forms of collaborative robot arms in industry, assesses safety and regulatory standards based on ISO/TS 15066, and explores future directions for human-robot collaboration in light of evolving EU Machinery Directive 2006/42/EC regulations.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

In this review of autonomous robotic surgery, the authors explore the integration of AI and machine learning in surgical procedures, detailing both the advancements and challenges of these technologies, including ethical concerns and current regulatory frameworks.

This study found that generic quality of life questionnaires, like the SF-36 and DLQI, are not sensitive enough to detect differences in health-related quality of life between patients with varying severity of alopecia areata.

This study employed multiple linear regressions to analyze hydantoin analogues and produced a model with strong predictive abilities for designing new androgen receptor modulators.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This study observed significant differences in oxytocin receptor expression and stem cell migration in a valproic acid-induced rat model of autism, with male rats showing notably reduced oxytocin receptor expression compared to their normal counterparts, highlighting potential gender differences in susceptibility to autism-related brain disturbances.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

In this study, YK11 was found to promote osteoblast cell proliferation and differentiation through activation of non-genomic signaling pathways in mouse osteoblast cells.

In this study, the MPV/PC ratio was identified as a potential tool for assessing disease activity in alopecia areata, with higher ratios in active and severe cases compared to inactive and mild/moderate ones.